Association of sodium-glucose cotransporter-2 inhibitors with outcomes in type 2 diabetes with reduced and preserved left ventricular ejection fraction: Analysis from the CVD-REAL 2 study

CVD-REAL Invest Study Grp; Carolyn S. P. Lam; Avraham Karasik; Cheli Melzer-Cohen; Matthew A. Cavender; Shun Kohsaka; Anna Norhammar; Marcus Thuresson; Hungta Chen; Eric Wittbrodt; Peter Fenici; Mikhail Kosiborod

doi:10.1111/dom.14356

Association of sodium-glucose cotransporter-2 inhibitors with outcomes in type 2 diabetes with reduced and preserved left ventricular ejection fraction: Analysis from the CVD-REAL 2 study

CVD-REAL Invest Study Grp, Carolyn S. P. Lam^*, Avraham Karasik, Cheli Melzer-Cohen, Matthew A. Cavender, Shun Kohsaka, Anna Norhammar, Marcus Thuresson, Hungta Chen, Eric Wittbrodt, Peter Fenici, Mikhail Kosiborod

^*Corresponding author for this work

Cardiovascular Centre (CVC)

Research output: Contribution to journal › Article › Academic › peer-review

15 Citations (Scopus)

72 Downloads (Pure)

Abstract

This study of real-world data from the Maccabi database in Israel compared the risk of heart failure hospitalization (HHF) or death in patients with type 2 diabetes (T2D) initiating sodium-glucose cotransporter-2 (SGLT2) inhibitors versus other glucose-lowering drugs (OGLDs) according to baseline left ventricular (LV) ejection fraction (EF). After propensity-matching patients by baseline EF there were 10 614 episodes of treatment initiation; 57% had diabetes for >10 years, the mean glycated haemoglobin level was 66 mmol/mol (8.2%), similar to 43% had cardiovascular disease, similar to 7% had heart failure and similar to 20% had chronic kidney disease. A total of 2876 patients (similar to 9%) had reduced EF (

Original language	English
Number of pages	5
Journal	Diabetes obesity & metabolism
DOIs	https://doi.org/10.1111/dom.14356
Publication status	Published - 23-Mar-2021

Keywords

diabetes
ejection fraction
heart failure hospitalization
mortality
real&#8208
world evidence

Access to Document

10.1111/dom.14356Licence: CC BY

Association of sodium-glucose cotransporter-2 inhibitorsFinal publisher's version, 588 KBLicence: CC BY

Handle.net

Persistent link

Cite this

CVD-REAL Invest Study Grp, Lam, C. S. P., Karasik, A., Melzer-Cohen, C., Cavender, M. A., Kohsaka, S., Norhammar, A., Thuresson, M., Chen, H., Wittbrodt, E., Fenici, P., & Kosiborod, M. (2021). Association of sodium-glucose cotransporter-2 inhibitors with outcomes in type 2 diabetes with reduced and preserved left ventricular ejection fraction: Analysis from the CVD-REAL 2 study. Diabetes obesity & metabolism. https://doi.org/10.1111/dom.14356

@article{18a7fb1be078496f81dbf2a5a49cfd9b,

title = "Association of sodium-glucose cotransporter-2 inhibitors with outcomes in type 2 diabetes with reduced and preserved left ventricular ejection fraction: Analysis from the CVD-REAL 2 study",

abstract = "This study of real-world data from the Maccabi database in Israel compared the risk of heart failure hospitalization (HHF) or death in patients with type 2 diabetes (T2D) initiating sodium-glucose cotransporter-2 (SGLT2) inhibitors versus other glucose-lowering drugs (OGLDs) according to baseline left ventricular (LV) ejection fraction (EF). After propensity-matching patients by baseline EF there were 10 614 episodes of treatment initiation; 57% had diabetes for >10 years, the mean glycated haemoglobin level was 66 mmol/mol (8.2%), similar to 43% had cardiovascular disease, similar to 7% had heart failure and similar to 20% had chronic kidney disease. A total of 2876 patients (similar to 9%) had reduced EF (",

keywords = "diabetes, ejection fraction, heart failure hospitalization, mortality, real&#8208, world evidence",

author = "{CVD-REAL Invest Study Grp} and Lam, {Carolyn S. P.} and Avraham Karasik and Cheli Melzer-Cohen and Cavender, {Matthew A.} and Shun Kohsaka and Anna Norhammar and Marcus Thuresson and Hungta Chen and Eric Wittbrodt and Peter Fenici and Mikhail Kosiborod",

year = "2021",

month = mar,

day = "23",

doi = "10.1111/dom.14356",

language = "English",

journal = "Diabetes obesity & metabolism",

issn = "1462-8902",

publisher = "Wiley",

}

CVD-REAL Invest Study Grp, Lam, CSP, Karasik, A, Melzer-Cohen, C, Cavender, MA, Kohsaka, S, Norhammar, A, Thuresson, M, Chen, H, Wittbrodt, E, Fenici, P & Kosiborod, M 2021, 'Association of sodium-glucose cotransporter-2 inhibitors with outcomes in type 2 diabetes with reduced and preserved left ventricular ejection fraction: Analysis from the CVD-REAL 2 study', Diabetes obesity & metabolism. https://doi.org/10.1111/dom.14356

Association of sodium-glucose cotransporter-2 inhibitors with outcomes in type 2 diabetes with reduced and preserved left ventricular ejection fraction: Analysis from the CVD-REAL 2 study. / CVD-REAL Invest Study Grp ; Lam, Carolyn S. P.; Karasik, Avraham et al.
In: Diabetes obesity & metabolism, 23.03.2021.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Association of sodium-glucose cotransporter-2 inhibitors with outcomes in type 2 diabetes with reduced and preserved left ventricular ejection fraction

T2 - Analysis from the CVD-REAL 2 study

AU - CVD-REAL Invest Study Grp

AU - Lam, Carolyn S. P.

AU - Karasik, Avraham

AU - Melzer-Cohen, Cheli

AU - Cavender, Matthew A.

AU - Kohsaka, Shun

AU - Norhammar, Anna

AU - Thuresson, Marcus

AU - Chen, Hungta

AU - Wittbrodt, Eric

AU - Fenici, Peter

AU - Kosiborod, Mikhail

PY - 2021/3/23

Y1 - 2021/3/23

N2 - This study of real-world data from the Maccabi database in Israel compared the risk of heart failure hospitalization (HHF) or death in patients with type 2 diabetes (T2D) initiating sodium-glucose cotransporter-2 (SGLT2) inhibitors versus other glucose-lowering drugs (OGLDs) according to baseline left ventricular (LV) ejection fraction (EF). After propensity-matching patients by baseline EF there were 10 614 episodes of treatment initiation; 57% had diabetes for >10 years, the mean glycated haemoglobin level was 66 mmol/mol (8.2%), similar to 43% had cardiovascular disease, similar to 7% had heart failure and similar to 20% had chronic kidney disease. A total of 2876 patients (similar to 9%) had reduced EF (

AB - This study of real-world data from the Maccabi database in Israel compared the risk of heart failure hospitalization (HHF) or death in patients with type 2 diabetes (T2D) initiating sodium-glucose cotransporter-2 (SGLT2) inhibitors versus other glucose-lowering drugs (OGLDs) according to baseline left ventricular (LV) ejection fraction (EF). After propensity-matching patients by baseline EF there were 10 614 episodes of treatment initiation; 57% had diabetes for >10 years, the mean glycated haemoglobin level was 66 mmol/mol (8.2%), similar to 43% had cardiovascular disease, similar to 7% had heart failure and similar to 20% had chronic kidney disease. A total of 2876 patients (similar to 9%) had reduced EF (

KW - diabetes

KW - ejection fraction

KW - heart failure hospitalization

KW - mortality

KW - real&#8208

KW - world evidence

U2 - 10.1111/dom.14356

DO - 10.1111/dom.14356

M3 - Article

SN - 1462-8902

JO - Diabetes obesity & metabolism

JF - Diabetes obesity & metabolism

ER -

Association of sodium-glucose cotransporter-2 inhibitors with outcomes in type 2 diabetes with reduced and preserved left ventricular ejection fraction: Analysis from the CVD-REAL 2 study

Abstract

Keywords

Access to Document

Handle.net

Fingerprint

Cite this